Atamyo Therapeutics to Present Corporate Overview and Pipeline Updates at 6 Upcoming Conferences

Atamyo Therapeutics, a biotechnology firm dedicated to developing advanced gene therapies for neuromuscular diseases, has recently announced its participation in six major conferences across the US and Europe. These events will provide a platform for the company to showcase its progress in treating limb-girdle muscular dystrophies (LGMDs).

CEO Stephan Degove is slated to present a corporate overview at three significant forums. The first is Sach’s 20th Annual Biotech in Europe Forum, which will take place in Basel, Switzerland, from September 25-26, 2024. Degove’s presentation is scheduled for September 25 at 11:40 am CEST in the Ruby Room. The second event is Chardan's 8th Annual Genetic Medicines Conference in New York City, occurring from September 30 to October 1, 2024. His presentation here is set for September 30 at 11:00 am US EDT in the Embassy Room. Finally, Degove will speak at the Cell & Gene Meeting on the Mesa, held in Phoenix, AZ, from October 7-9, 2024, with his presentation scheduled for October 8 at 5:45 pm US MST in the FLW Ballroom F.

Atamyo will also feature prominently at the 29th Annual Congress of the World Muscle Society, hosted in Prague's Congress Centre, Czech Republic, from October 8-12, 2024. Two key communications will be presented during this event. The first, titled “Preliminary results from a Phase 1-2 gene therapy study of ATA-100, AAV9 vector encoding FKRP, in patients with Limb Girdle Muscular Dystrophy R9,” will be an oral presentation by S. Olivier on October 12 from 8:00 am to 8:15 am CEST in the Congress Hall. The second, “MRI characterization of the cardiac involvement in LGMD2i/R9,” will be presented by JY Hogrel from the Institute of Myology, Paris, as a poster (number 87P) on October 9 from 5:15 pm to 6:15 pm CEST in Forum Hall.

Further, Atamyo’s work will be highlighted at the European Society of Gene & Cell Therapy’s 31st Annual Congress, scheduled for October 22-25, 2024, in La Nuvola, Rome, Italy. Two posters will be presented during Poster Session II on October 23 from 1:30 pm to 3:00 pm CEST. The first poster, authored by E Thevenot from Genethon and titled “Development of a quantitative alpha-dystroglycan glycosylation test in patients with Limb Girdle Muscular Dystrophy R9 treated in ATA-001-FKRP open-label multicenter AAV trial,” will be poster number P0088. The second poster, “Natural history of limb girdle muscular dystrophy R9: two-year follow-up of a European cohort,” by S Olivier from Atamyo, will be poster number P0264.

Atamyo’s contributions will also be featured at the ASGCT’s Breakthroughs in Muscular Dystrophy Conference in Chicago, IL, on November 19-20, 2024. Two critical communications will be presented here. E. Gicquel from Genethon will deliver an oral presentation titled “Development of Gene Therapy for LGMD-R9” on November 19 from 5:15 pm to 5:30 pm US CDT in the Great Lakes East Ballroom at the Westin Michigan Avenue Hotel. Additionally, a poster titled “Overcoming Phenotypic Variability in Dystrophic Models: A Machine Learning Method for Refined Gene Therapy Evaluation,” by E. Brureau from Genethon, will be session P27, scheduled for November 16, 2024, from 8:00 am to 7:00 pm US CDT in the Great Lakes East Ballroom at the Westin Michigan Avenue Hotel.

Atamyo Therapeutics has also achieved a significant milestone with the publication of a paper in Nature Communications. The study, titled “An engineered AAV targeting integrin alphaV beta 6 presents improved myotropism across species,” was authored by Ai Vu Hong from Genethon and describes the development of the next-generation LICA-1 capsid. This research, spearheaded by Isabelle Richard, Ph.D., Atamyo’s Chief Scientific Officer, aims to enhance the efficacy and safety of gene therapies for muscle diseases. Atamyo holds the rights to use the LICA-1 capsid for cardiomyopathies indications.

Atamyo Therapeutics, a clinical-stage biopharmaceutical company, is committed to advancing gene therapies for neuromuscular diseases, leveraging its expertise in AAV-based therapies to develop treatments for various forms of limb-girdle muscular dystrophies.